United Therapeutics Announces First Patient Enrolled in Phase III TETON 2 Study of Tyvaso in Patients with Idiopathic Pulmonary Fibrosis

United Therapeutics Corporation announced that the first patient has enrolled in the Phase III TETON2 study which will evaluate Tyvaso in 396 adult patients with idiopathic pulmonary fibrosis at sites outside the United States and Canada.